Daurismo

Chemical Nameglasdegib
Dosage FormTablet (oral; 25 mg, 100 mg)
Drug ClassInhibitors
SystemBlood
CompanyAgios Pharmaceuticals Inc.
Approval Year2018

Indication

  • To treat newly-diagnosed acute myeloid leukemia in patients ≥ 75 years of age in conjunction with low-dose cytarabine.
  • To treat newly-diagnosed acute myeloid leukemia in patients with comorbidities that preclude use of intensive induction chemotherapy in conjunction with low-dose cytarabine.
Last updated on 6/10/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Daurismo (Glasdegib) Prescribing Information 2018Pfizer Inc., New York